Download PDF
Senologie - Zeitschrift für Mammadiagnostik und -therapie 2008; 5(3): 162-167
DOI: 10.1055/s-2008-1076813
Wissenschaftliche Arbeit

© Georg Thieme Verlag KG Stuttgart ˙ New York

Knochenstoffwechsel in der Onkologie

Tumor- und therapieinduzierte Veränderungen im KnochenstoffwechselBone Metabolism in OncologyTumor- and Therapy-Induced Changes in Bone MetabolismH. Seeger1 , T. Fehm1 , B. Krämer1 , E. Solomayer1 , P. Hadji2
  • 1Universitäts-Frauenklinik Tübingen
  • 2Universitäts-Frauenklinik Marburg
Further Information

Publication History

2007

2008

Publication Date:
30 September 2008 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Veränderungen im Knochenstoffwechsel in der Onkologie sind nicht nur von Bedeutung durch die Bildung von Knochenmetastasen als Folge von Primärerkrankungen wie Mammakarzinom oder Prostatakrebs, sondern treten in jüngster Zeit auch in den Blickpunkt aufgrund der adjuvanten Therapie des Mammakarzinoms, besonders mit den Aromatasehemmern, die zu einer ausgeprägten Östrogendeprivation führen. Ziel dieser Übersichtsarbeit ist es, neben dem aktuellen Stand der Forschung auch Überblicke über Diagnose und Behandlungsstrategie hinsichtlich Veränderungen des Knochenstoffwechsels im Bereich der Onkologie zu geben.

Abstract

Changes in bone metabolism in oncological patients have a clinical significance for the formation of bone metastasis during the course of primary diseases such as breast cancer or prostate cancer. In addition, attention is currently being focused on bone metabolism changes during adjuvant therapies for breast cancer, especially after the administration of aromatase inhibitors which lead to estrogen deprivation. The aim of the present review is to give an overview of the current scientific state of the art together with a summary on the diagnosis and treatment strategies with respect to changes of bone metabolism in oncology.

Schlüsselwörter

Knochenstoffwechsel - Onkologie - Diagnose - Therapie

Key words

bone metabolism - oncology - diagnosis - therapy

Literatur

  • 1 Coleman R E, Rubens R D. The clinical course of bone metastases from breast cancer.  Br J Cancer. 1987;  55 61-66
    CrossrefPubMedGoogle Scholar
  • 2 Solomayer E-F, Diel I J, Wallwiener D, Bastert G. Das primär ossär metastasierte Mammakarzinom. Untersuchungen zu Prognose, Verlauf und Therapie.  Geburtsh Frauenheilk. 1997;  57 629-636
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Solomayer E-F, Diel I J, Gollan C, Bastert G. Localization of the first metastases in breast cancer. Analysis to clinical course, prognosis and therapy.  Breast Cancer Res Treat Cancer. 2000;  59 271-278
    CrossrefPubMedGoogle Scholar
  • 4 Coleman R E, Seaman J J. The role of zoledronic acid in cancer: clinical studies in the treatment and prevention of bone metastases.  Semin Oncol. 2001;  28 11-16
    PubMedGoogle Scholar
  • 5 Käkönen S-M, Mundy G R. Mechanisms of osteolytic bone metastases in breast carcinoma.  Cancer. 2003;  97 834-839
    CrossrefPubMedGoogle Scholar
  • 6 Guise T A, Yin J J, Mohammad K S. Role of endothelin-1 in osteoblastic bone metastases.  Cancer. 2003;  97 779-784
    CrossrefPubMedGoogle Scholar
  • 7 Demers L M, Costa L, Chincilli V, Gaydos L, Curley E, Lipton A. Biochemical markers of bone turnover in patients with metastatic bone disease.  Clin Chem. 1995;  41 1489-1494
    PubMedGoogle Scholar
  • 8 Yoneda T, Hashimoto N, Hiraga T. Bisphosphonate actions on cancer.  Calcif Tissue Int. 2003;  73 315-318
    CrossrefPubMedGoogle Scholar
  • 9 Bolotin H H. Inaccuracies inherent in dual-energy X‐ray absorptiometry in vivo bone mineral densitometry may flaw osteopenic / osteoporotic interpretations and mislead assessment of antiresorptive therapy effectiveness.  Bone. 2001;  28 548-555
    CrossrefPubMedGoogle Scholar
  • 10 Dachverband Osteologie e.V. (DVO) .Evidenzbasierte Konsensus-Leitlinie zur Osteoporose. Stuttgart; Schattauer Verlag 2006
    Google Scholar
  • 11 Wüster C, Heilmann P, Pereira-Lima J, Schlegel J, Anstätt K, Soballa T. Quantitative ultrasonometry (QUS) for the evaluation of osteoporosis risk: reference data for various measurement sites, limitations and application possibilities.  Exp Clin Endocrinol Diabetes. 1998;  106 277-288
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Hadji P, Hars O, Wüster C, Bock K, Alberts U S, Bohnet H G, Emons G, Schulz K D. Stiffness index identifies patients with osteoporotic fractures better than ultrasound velocity or attenuation alone.  Maturitas. 1999;  31 221-226
    CrossrefPubMedGoogle Scholar
  • 13 Kann P H. Bone densitometry and ultrasound studies of the bone: methods, indications and efficacy.  Orthopäde. 2001;  30 437-443
    CrossrefPubMedGoogle Scholar
  • 14 Kraemer D F, Nelson H D, Bauer D C, Helfand M. Economic comparison of diagnostic approaches for evaluating osteoporosis in older women.  Osteoporos Int. 2006;  17 68-76
    CrossrefPubMedGoogle Scholar
  • 15 Marín F, González-Macías J, Díez-Pérez A, Palma S, Delgado-Rodríguez M. Relationship between bone quantitative ultrasound and fractures: a meta-analysis.  J Bone Miner Res. 2006;  21 1126-1135
    CrossrefPubMedGoogle Scholar
  • 16 Hadji P. Possibilities and limitations of quantitative ultrasonometry in clinical practice.  Dtsch Med Wochenschr. 2003;  128 951-953
    Article in Thieme ConnectPubMedGoogle Scholar
  • 17 Vehmanen L, Saarto T, Elomaa I, Mäkelä P, Välimäki M, Blomqvist C. Long-term impact of chemotherapyinduced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment.  Eur J Cancer. 2001;  37 2373-2378
    CrossrefPubMedGoogle Scholar
  • 18 Gnant M FX, Mlineritsch B, Luschin-Ebengreuth G, Grampp S, Kaessmann H, Schmid M et al. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group.  J Clin Oncol. 2007;  25 820-828
    CrossrefPubMedGoogle Scholar
  • 19 Pfeilschifter J, Diehl I. Osteoporosis due to cancer treatment: pathogenesis and management.  J Clin Onc. 2000;  18 1570-1593
    PubMedGoogle Scholar
  • 20 Lower E E, Blau R, Gazder P, Tummala R. The risk of premature menopause induced by chemotherapy for early breast cancer.  J Women's Health. 1999;  8 949-954
    PubMedGoogle Scholar
  • 21 Ataya K, Moghissi K. Chemotherapy induced premature ovarian failure: Mechanisms and prevention.  Steroids. 1989;  54 607-626
    CrossrefPubMedGoogle Scholar
  • 22 Howell S J, Berger G, Adams J E, Shalet S M. Bone mineral density in women with cytotoxicinduced ovarian failure.  Clin Endocrin. 1998;  49 397-402
    CrossrefPubMedGoogle Scholar
  • 23 LeBoff M S, Neuberg D, Fowler K, Shapiro C L. Chemotherapy-induced amenorrhea in women with breast cancer leads to marked bone loss.  Bone. 1998;  23 621
    PubMedGoogle Scholar
  • 24 Headley J A, Theriault R L, LeBlanc A D, Vassilopoulou-Sellin R, Hortobagyi G N. Pilot study of bone mineral density in breast cancer patients treated with adjuvant chemotherapy.  Cancer Investigation. 1998;  16 6-11
    CrossrefPubMedGoogle Scholar
  • 25 Shapiro C L, Manola J, Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer.  J Clin Oncol. 2001;  19 3306-3311
    PubMedGoogle Scholar
  • 26 Davies J H, Evans B AJ, Jenney M EM, Gregory J W. In vitro effects of chemotherapeutic agents on human osteoblast-like cells.  Calcif Tissue Int. 2002;  70 408-415
    CrossrefPubMedGoogle Scholar
  • 27 Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A, Sahmoud T. The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group . Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.  Cancer. 2003;  98 1802-1810
    CrossrefPubMedGoogle Scholar
  • 28 Eastell R, Hannon R A, Cuzick J, Dowsett M, Clack G, Adams J E. ATAC Trialists' group. Effect of an aromatase inhibitor on bmd ad bone turnover markers: 2-year results of Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial.  J Bone Miner Res. 2006;  21 1215-1223
    CrossrefPubMedGoogle Scholar
  • 29 Thurlimann B, Keshaviah A, Coates A S, Mouridsen H, Mauriac L, Forbes J F, Paridaens R, Castiglione-Gertsch M, Gelber R D, Rabaglio M, Smith I, Wardley A, Price K N, Goldhirsch A. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.  N Engl J Med. 2005;  353 2747-2757
    CrossrefPubMedGoogle Scholar
  • 30 Jones S E, Cantrell J, Vukelja S, Pippen J, O'Shaughnessy J, Blum J L, Brooks R, Hartung N L, Negron A G, Richards D A, Rivera R, Holmes F A, Chittoor S, Whittaker T L, Bordelon J H, Ketchel S J, Davis J C, Ilegbodu D, Kochis J, Asmar L. The effect of tamoxifen (T) or exemestane (E) on bone mineral density (BMD) after 1 year of adjuvant treatment of postmenopausal women with early breast cancer.  J Clin Oncol. 2005;  23 31s
    PubMedGoogle Scholar
  • 31 Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C, Hilfrich J, Kwasny W, Menzel C, Samonigg H, Seifert M, Gademann G, Kaufmann M, Wolfgang J. Switching of postmenopausal women with endocrineresponsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: Combined results of ABCSG trial 8 and ARNO 95 trial.  Lancet. 2005;  366 455-462
    CrossrefPubMedGoogle Scholar
  • 32 Coombes R C, Kilburn L S, Paridaens R, Coleman R E, Jones S E, Jassem J, Van de Velde C J, Delozier T, Alvarez I, Del Mastro L, Ortmann O, Diedrich K, Coates A S, Bajetta E, Holmberg S B, Dodwell D, Mickiewicz E, Andersen J, Lønning P E, Cocconi G, Forbes J, Castiglione M, Stuart N, Stewart A, Fallowfield L J, Bertelli G, Hall E, Bogle R G, Carpentieri M, Colajori E, Subar M, Ireland E, Bliss J M. Survival and safety of exemestane versus tamoxifen after 2 – 3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial.  Lancet. 2007;  369 559-570
    CrossrefPubMedGoogle Scholar
  • 33 Goss P E, Ingle J N, Martino S, Robert N J, Muss H B, Piccart M J, Castiglione M, Tu D, Shepherd L E, Pritchard K I, Livingston R B, Davidson N E, Norton L, Perez E A, Abrams J S, Therasse P, Palmer M J, Pater J L. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.  N Engl J Med. 2003;  349 1793-1802
    CrossrefPubMedGoogle Scholar
  • 34 Perez E A, Josse R G, Pritchard K I, Ingle J N, Martino S, Findlay B P, Shenkier T N, Tozer R G, Palmer M J, Shepherd L E, Liu S, Tu D, Goss P E. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: A companion study to NCIC CTG MA.17.  J Clin Oncol. 2006;  24 3629-3635
    CrossrefPubMedGoogle Scholar
  • 35 Love R R, Mazess R B, Barden H S, Epstein S, Newcomb P A, Jordan V C, Carbone P P, DeMets D L. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer.  N Engl J Med. 1992;  326 852-856
    CrossrefPubMedGoogle Scholar
  • 36 Powles T J, McCloskey E, Paterson A H, Ashley S, Tidy V A, Nevantaus A, Rosenqvist K, Kanis J. Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer.  J Natl Cancer Inst. 1998;  90 704-708
    CrossrefPubMedGoogle Scholar
  • 37 Hillner B E, Ingle J N, Chlebowski Gralow R TJ, Yee G C, Janjan N A, Cauley J A, Blumenstein B A, Albain K S, Lipton A, Brown S. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer.  J Clin Oncol. 2003;  21 4042-4047
    CrossrefPubMedGoogle Scholar
  • 38 Hadji P, Aapro M, Brufsky A, Tubiana-Hulin Guise A T, Body J J. Practical guidance for the prevention of aromatase inhibitor-associated bone loss in women with breast cancer.  Breast Cancer Res Treat. 2007;  106, Suppl 1 Abstract 504
    PubMedGoogle Scholar
  • 39 Brufsky A, Harker W G, Beck J T, Carroll R, Tan-Chiu E, Seidler C, Hohneker J, Lacerna L, Petrone S, Perez E A. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer.  J Clin Oncol. 2007;  25 3194-3197
    CrossrefPubMedGoogle Scholar

Prof. Dr. H. Seeger

Schwerpunkt für Endokrinologie und Menopause
Universitäts-Frauenklinik

Calwer Straße 7

72076 Tübingen

Email: endo.meno@med.uni-tuebingen.de

      >